Scottish Patients to Benefit from New, Convenient Treatment Option for Rheumatoid Arthritis
Today a new subcutaneous formulation of RoActemra (tocilizumab) has been accepted for use on the NHS in Scotland for the treatment of rheumatoid arthritis (RA). This announcement by the Scottish Medicines Consortium (SMC), which advises NHS Scotland on prescribing new treatments, means that patients receiving treatment with RoActemra can now be in control of where and when they have their treatment, giving them freedom to manage the condition convenient to their lifestyle, whether at hospital or at home. This is especially important for the vast number of patients in Scotland without easy access to their nearest hospital due to their rural or remote location.
RoActemra is the first anti IL-6 receptor inhibitor to be available as both subcutaneous and intravenous (IV) formulation, for both combination therapy with methotrexate (MTX) and for use without MTX for those patients who cannot or will not continue with MTX. It provides an important treatment option for the 20–40% of RA patients that experience incomplete responses and/or adverse events with MTX as, in an IV trial, it was shown that they are almost four times more likely to achieve disease remission from RoActemra (tocilizumab) without MTX compared to patients taking the most widely prescribed anti TNF, Humira (adalimumab) without MTX (39.9% vs 10.5%).
Commenting on the SMC decision, Professor Ernest Choy, Professor of Rheumatology, Cardiff Institute
of Infection & Immunity, remarked: “Today’s positive decision brings a valuable option in the management of this chronic condition for people with RA in Scotland, of which patient choice is extremely significant. The convenience of self-administration in a subcutaneous formulation not only benefits patients, giving them more choice and better control of their disease, but also improves costeffectiveness by freeing up capacity in Scottish hospitals.”
Today’s approval from the SMC was based on data from the phase III SUMMACTA and BREVACTA studies. SUMMACTA showed that the efficacy and tolerability of subcutaneous RoActemra was comparable with the intravenous formulation. In addition, long-term efficacy and reduced progression of joint damage over 48 weeks was demonstrated compared to placebo in the BREVACTA study. With comparable efficacy and tolerability to the intravenous formulation, the addition of the subcutaneous formulation provides clinicians and patients, particularly those unable to take MTX, with more flexibility to choose a treatment method that suits their needs.
“RA is an extremely debilitating disease that can affect every aspect of a person’s life,” said Sheila MacLeod, Scottish Ambassador at NRAS. “With the availability of this treatment option, sufferers in Scotland now have much needed flexibility and choice, giving them a better opportunity to remain active and get on with their lives as normally as possible.”
RoActemra is licenced for intravenous use every 4 weeks and the subcutaneous formulation is administered once a week via a pre-filled syringe. The most common adverse reactions reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache, elevated blood pressure, and increased liver enzymes. The serious adverse reactions reported in clinical studies include serious infections, gastrointestinal perforations and hypersensitivity reactions including anaphylaxis.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance